Original Research
Published on 15 Mar 2021
Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.628124
- 13,006 views
- 75 citations
